Gilead Sciences ((GILD)), Arcus Biosciences ((RCUS)), Gilead Sciences (($CC:GILD.CUR)) announced an update on their ongoing clinical study.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Gilead Sciences and Arcus Biosciences are conducting a Phase 1b/2 study to evaluate the efficacy and safety of etrumadenant-based treatment combinations in patients with metastatic colorectal cancer. The study, officially titled ‘A Phase 1b/2, Open-Label, Randomized Platform Study Evaluating The Efficacy and Safety of AB928 Based Treatment Combinations in Patients With Metastatic Colorectal Cancer,’ aims to assess the antitumor activity and safety of these combinations.
The interventions being tested include etrumadenant, a dual adenosine receptor antagonist, in combination with zimberelimab, an anti-PD-1 monoclonal antibody, and other agents like bevacizumab and mFOLFOX-6 regimen. These are designed to target cancer cells more effectively.
The study employs a randomized, parallel intervention model with single masking for outcomes assessors. Its primary purpose is treatment-focused, aiming to establish the safety and efficacy of the drug combinations.
The study began on May 10, 2021, and is currently active but not recruiting. The latest update was submitted on June 25, 2025. These dates are crucial for tracking the study’s progress and potential market entry.
This update could impact Gilead Sciences’ and Arcus Biosciences’ stock performance, as positive results may enhance investor confidence and market position. The study’s outcomes could also influence the competitive landscape in cancer treatment.
The study is ongoing, with further details available on the ClinicalTrials portal.